Abstract
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Benzamides
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Eosinophils / pathology
-
Female
-
Gene Rearrangement
-
Humans
-
Hypereosinophilic Syndrome / drug therapy*
-
Hypereosinophilic Syndrome / genetics
-
Imatinib Mesylate
-
Leukocyte Count
-
Male
-
Middle Aged
-
Oncogene Proteins, Fusion / genetics
-
Piperazines / administration & dosage*
-
Piperazines / therapeutic use
-
Pyrimidines / administration & dosage*
-
Pyrimidines / therapeutic use
-
Receptor, Platelet-Derived Growth Factor alpha / genetics
-
Treatment Outcome
-
Young Adult
-
mRNA Cleavage and Polyadenylation Factors / genetics
Substances
-
Benzamides
-
Oncogene Proteins, Fusion
-
Piperazines
-
Pyrimidines
-
mRNA Cleavage and Polyadenylation Factors
-
Imatinib Mesylate
-
FIP1L1-PDGFRA fusion protein, human
-
Receptor, Platelet-Derived Growth Factor alpha